Healthcare / Health Information ServicesTokyo
$585.00
-76.00 (-11.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-923.6M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.4B
P/E
27.7x
↑EV/EBITDA
N/A
•ROE
-25.3%
↓Gross Margin
29.7%
↓Debt/Equity
0.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+14.6%
FCF CAGR
—
FCF margin
-13.6%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.01B · net income $-807.2M · FCF $-678.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.01B | $5.01B | $4.41B | $2.99B | $3.33B |
| Net Income | $-807.2M | $-807.2M | $-664.9M | $-410.8M | $283.9M |
| EBITDA | $-148.7M | $-148.7M | $-222.7M | $-246.9M | $478.0M |
| EPS | -63.70 | -63.70 | -53.33 | -38.68 | 26.72 |
| Gross Margin | 29.7% | 29.7% | 32.2% | 42.0% | 53.4% |
| Operating Margin | -15.8% | -15.8% | -11.3% | -10.6% | 10.5% |
| Net Margin | -16.1% | -16.1% | -15.1% | -13.7% | 8.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.77 | 0.77 | 0.37 | 0.32 | 0.00 |
| Current Ratio | 1.32 | 1.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-678.9M | $-678.9M | $-923.6M | $-1.04B | $68.2M |
| Returns | |||||
| ROE | -25.3% | -25.3% | -16.8% | -32.7% | 18.4% |
| Valuation | |||||
| P/E | 27.69 | 27.69 | — | — | 55.33 |
| EV/EBITDA | — | — | — | — | 30.64 |
| P/B | 2.32 | 2.32 | 7.51 | 16.97 | 10.18 |
| Growth & Yield | |||||
| Revenue Growth | 13.5% | 13.5% | 47.5% | -10.2% | — |
| EPS Growth | -19.4% | -19.4% | -37.9% | -244.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-53.33 → -63.70
Residual
+33.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.